Complaint in Altimeo Asset Management, of France v. WuXi PharmaTech (Cayman) Inc., New WuXi Life Science Limited, WuXi Merger Limited, G&C Partnership LP, Boyu Capital Fund II LP, Hillhouse Capital Fund II LP, G&C IV Limited, and Sequoia Capital China Growth Fund III LP, all of the Cayman Islands; ABG II-WX Limited, Yunfeng II WX Limited, and Constant Cypress Limited, all of the British Virgin Islands; Yinfu Capital Management Co., and Ping An Life Insurance Company of China Ltd., both of China; SPDB International Holdings Limited, of Hong Kong; Temasek Life Sciences Private Limited, of Singapore; Ge Li, Edward Hu, Ning Zhao, Xiaozhong Liu, and Zhaohui Zhang at the U. S. District Court for the Southern District of New York.
37
February 21, 2019
WuXi PharmaTech (Cayman) Inc., Ge Li, Edward Hu, Ning Zhao, Xiaozhong Liu, Zhaohui Zhang, New WuXi Life Science Limited, WuXi Merger Limited, G&C Partnership LP, ABG II-WX Limited, Boyu Capital Fund II LP, Hillhouse Capital Fund II LP, Ping An Life Insurance Company of China Ltd., Temasek Life Sciences Private Limited, G&C IV Limited, Yinfu Capital Management Co., Yunfeng II WX Limited, Sequoia Capital China Growth Fund III LP, Constant Cypress Limited, SPDB International Holdings Limited
Topics
British Virgin Islands Cayman Islands China France Hong KongKeywords
ABG II-WX Limited Altimeo Asset Management Boyu Capital Fund II LP Constant Cypress Limited Edward Hu